Develop Clones In Just 9 Weeks From Transfection With Up To 4X Titer

If your cell line development (CLD) timelines feel bloated and your titers aren't where they need to be, the problem likely starts with positional effects in CHO (Chinese Hamster Ovary) cell integration. Traditional random integration methods produce heterogeneous gene expression and force you to screen far more clones than you should have to. Transposon-based, semi-targeted integration addresses this directly: by inserting the full construct at multiple genomic locations via a cut-and-paste mechanism, you get consistent expression across cells and dramatically fewer non-producers to wade through.

The SynWeave platform pairs this approach with high-throughput clone screening using the Ambr 250 miniaturized bioreactor system, Design of Experiments (DoE), and Process Analytical Technology (PAT) within a Quality by Design (QbD) framework. The result is a 27-week path to stable clones that saves up to 10 weeks versus conventional methods. One client went from 0.8 g/L in 22 days to 4.8 g/L in 17 days. Integrated runs for IgG1 and IgG4 molecules consistently hit 5-7 g/L, with optimized processes reaching up to 10 g/L.

Access the full case study to assess whether this integrated approach fits your biologics manufacturing strategy.